Jacobio Pharma shared a post on LinkedIn:
“Jacobio Pharma Announces Exclusive Global Licensing Agreement with AstraZeneca for Pan-KRAS Inhibitor JAB-23E73
We are pleased to announce that Jacobio Pharma has entered into an exclusive global license agreement with AstraZeneca for our innovative Pan-KRAS inhibitor JAB-23E73.
Under the agreement, AstraZeneca will have exclusive rights to develop and commercialize JAB-23E73 outside China, while both companies will jointly develop and jointly commercialize the therapy in China.
KRAS mutations are among the most common oncogenic drivers, present in approximately 23% of all cancer patients. JAB-23E73 is currently in Phase I clinical trials in the U.S. and China, where early signals of anti-tumor activity have been observed.
This partnership reflects AstraZeneca’s global strength in oncology development and commercialisation, and marks a meaningful milestone in accelerating the worldwide advancement of JAB-23E73.
At Jacobio, we remain committed to advancing innovative medicines for patients worldwide and expanding our leadership across the KRAS pathway and next-generation immuno-oncology platforms.”
Andrea Wang-Gillam, Co-CEO at Jacobio Pharma, shared this post, adding:
“I am very excited about the potential of this partnership, extending beyond accelerating global development to maximizing this program’s scientific and commercial value worldwide.”
Matt Hellmann, Senior Vice President of Early Oncology and Precision Medicine at AstraZeneca, also shared a post about Licensing Agreement with Jacobio Pharma on LinkedIn:
“Today, we at AstraZeneca entered into a global licensing agreement with Jacobio Pharma for a pan-KRAS inhibitor in early-stage development. KRAS is among the most important oncogenes in cancer, and KRAS-driven cancers are a significant area of ongoing research.
Furthering our understanding of this modality may help inform future scientific advances in oncology. Congratulations to the teams behind making this deal happen!”
More posts about Andrea Wang-Gillam.